Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 40, 1519-1524, May 1, 1980]
© 1980 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuhas, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuhas, J. M.

Active versus Passive Absorption Kinetics as the Basis for Selective Protection of Normal Tissues by S-2-(3-Aminopropylamino)-ethylphosphorothioic Acid1

John M. Yuhas

Cancer Research and Treatment Center and Department of Radiology, University of New Mexico, Albuquerque, New Mexico 87131

Through an in vivo and in vitro analysis of the absorption kinetics of S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) in the normal tissues and solid tumors of mice, rats, and rabbits, it has been demonstrated that normal tissues actively concentrate WR-2721 against a concentration gradient, whereas solid tumors passively absorb it, or, if active concentration of WR-2721 is present in tumors, it operates at a far reduced rate relative to normal tissues. These observations can account for the ability of WR-2721 to selectively protect normal tissues against both radiation and alkylating agent injury.

1 Supported by Grants CA-21074-03 and CA-19326-02 A1 from the National Cancer Institute, Department of Health, Education, and Welfare.

Received 6/25/79. Accepted 2/ 1/80.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. P. Cotrim, F. Hyodo, K.-I. Matsumoto, A. L. Sowers, J. A. Cook, B. J. Baum, M. C. Krishna, and J. B. Mitchell
Differential Radiation Protection of Salivary Glands versus Tumor by Tempol with Accompanying Tissue Assessment of Tempol by Magnetic Resonance Imaging
Clin. Cancer Res., August 15, 2007; 13(16): 4928 - 4933.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. R. Kouvaris, V. E. Kouloulias, and L. J. Vlahos
Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector
Oncologist, June 1, 2007; 12(6): 738 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
M. Ozsahin, M. Betz, O. Matzinger, L. Bron, F. Luthi, P. Pasche, D. Azria, R. O. Mirimanoff, and A. Zouhair
Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Arch Otolaryngol Head Neck Surg, February 1, 2006; 132(2): 141 - 145.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Dai, A. M. Holmes, T. Nguyen, S. Davies, D. P. Theele, C. Verschraegen, and K. K. Leslie
A Potential Synergistic Anticancer Effect of Paclitaxel and Amifostine on Endometrial Cancer
Cancer Res., October 15, 2005; 65(20): 9517 - 9524.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
G. C. Jagetia, P. Venkatesh, and M. S. Baliga
Fruit Extract of Aegle marmelos Protects Mice Against Radiation-Induced Lethality
Integr Cancer Ther, December 1, 2004; 3(4): 323 - 332.
[Abstract] [PDF]

Home page
 Pharmacol. Rev.Home page
M. Rooseboom, J. N. M. Commandeur, and N. P. E. Vermeulen
Enzyme-Catalyzed Activation of Anticancer Prodrugs
Pharmacol. Rev., March 1, 2004; 56(1): 53 - 102.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Leong, E. H. Tan, K. W. Fong, E. Wilder-Smith, Y. K. Ong, B. C. Tai, L. Chew, S. H. Lim, J. Wee, K. M. Lee, et al.
Randomized Double-Blind Trial of Combined Modality Treatment With or Without Amifostine in Unresectable Stage III Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 1, 2003; 21(9): 1767 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Pluquet, S. North, A. Bhoumik, K. Dimas, Z.'e. Ronai, and P. Hainaut
The Cytoprotective Aminothiol WR1065 Activates p53 through a Non-genotoxic Signaling Pathway Involving c-Jun N-terminal Kinase
J. Biol. Chem., March 28, 2003; 278(14): 11879 - 11887.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. M. Abushamaa, T. A. Sporn, and R. J. Folz
Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen
Am J Physiol Lung Cell Mol Physiol, August 1, 2002; 283(2): L336 - L345.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
L. DUBOURG, C. MICHOUDET, P. COCHAT, and G. BAVEREL
Human Kidney Tubules Detoxify Chloroacetaldehyde, a Presumed Nephrotoxic Metabolite of Ifosfamide
J. Am. Soc. Nephrol., August 1, 2001; 12(8): 1615 - 1623.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. I. Koukourakis, G. Kyrias, S. Kakolyris, C. Kouroussis, C. Frangiadaki, A. Giatromanolaki, G. Retalis, and V. Georgoulias
Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study
J. Clin. Oncol., June 11, 2000; 18(11): 2226 - 2233.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Gelmon, E. Eisenhauer, C. Bryce, A. Tolcher, L. Mayer, E. Tomlinson, B. Zee, M. Blackstein, E. Tomiak, J. Yau, et al.
Randomized Phase II Study of High-Dose Paclitaxel With or Without Amifostine in Patients With Metastatic Breast Cancer
J. Clin. Oncol., October 1, 1999; 17(10): 3038 - 3047.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Hensley, L. M. Schuchter, C. Lindley, N. J. Meropol, G. I. Cohen, G. Broder, W. J. Gradishar, D. M. Green, R. J. Langdon Jr, R. B. Mitchell, et al.
American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants
J. Clin. Oncol., October 1, 1999; 17(10): 3333 - 3355.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. J. Weichert-Jacobsen, A. Bannowski, F. Kuppers, T. Loch, and M. Stockle
Direct Amifostine Effect on Renal Tubule Cells in Rats
Cancer Res., July 1, 1999; 59(14): 3451 - 3453.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
G. MINOTTI, G. CAIRO, and E. MONTI
Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
FASEB J, February 1, 1999; 13(2): 199 - 212.
[Abstract] [Full Text]

Home page
 J Oncol Pharm PractHome page
M. Summerhayes
Review : Amifostine and other chemoprotective agents in cancer chemotherapy: A brief review
Journal of Oncology Pharmacy Practice, December 1, 1995; 1(4): 21 - 31.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
N. F. Schor
A Neurologist's Approach to Neuroblastoma
J Child Neurol, January 1, 1992; 7(1): 93 - 98.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
N. F. Schor
Neuroblastoma: A Neurochemical Approach
J Child Neurol, July 1, 1991; 6(3): 220 - 228.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
D. J. GLOVER, L. SHAW, J. H. GLICK, E. SLATOPOLSKY, C. WEILER, M. ATTIE, and S. GOLDFARB
Treatment of Hypercalcemia in Parathyroid Cancer with WR-2721,5-2(3aminopropylamino) Ethyl-Phosphorothioic Acid
Ann Intern Med, July 1, 1985; 103(1): 55 - 57.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.